Friday, May 3, 2024
5/3/2024
PROJECT SUMMARY/ABSTRACT The Cyclotron Group at the University of Wisconsin–Madison (UW) produces radionuclides for medical and fundamental scientific investigations using a 16 MeV General Electric PETtrace cyclotron. This effort currently supports $237M of funded research led by UW principal investigators (PIs), an additional $95M in projects led by a nationally distributed user base, an estimated clinical service revenue of almost $1M per year, and its own internal portfolio of federal awards of approximately $1.2M per year. The broad base of stakeholders includes PIs in 12 UW departments and over three dozen clinical research studies. Recent growth in nuclear medicine applications of cyclotron-produced radionuclides has been dramatic, and demand exceeded production capacity on multiple occasions in 2022, despite the Cyclotron Group’s prioritization of UW clinical and basic research needs. To create independent UW production capacity of increasingly promising single photon-emitting computed tomography (SPECT) and theranostic radionuclides, this proposal will build a new cyclotron facility to house a commercial 30 MeV cyclotron adjacent to the existing School of Medicine and Public Health (SMPH) biomedical research facilities of the Wisconsin Institutes for Medical Research (WIMR). This machine will add capacity in every essential area: standard and radiometal PET radionuclides, theranostic beta and Auger- emitters, and both clinical and research application-oriented research. The new machine will also enhance the efficacy of the existing PETtrace cyclotron, focusing each machine’s efforts on its strengths and simultaneously supporting a nascent UW Institute for Theranostics and Particle Therapy; the Waisman Center’s and Alzheimer’s Disease Research Center’s portfolio of neurodegenerative imaging trials; the preclinical research of PIs working on stem cell, genetic, and viral therapy development in the Wisconsin National Primate Center and the Small Animal Imaging and Radiotherapy Facility; and the United States Department of Energy Isotope Production Network. The facility will contribute to meeting projected growth associated with FDA approvals of novel diagnostic and therapeutic radiopharmaceuticals. The proposed facility will more than quadruple existing capacity and add capability to make several new isotopes that are in demand for cutting edge medical diagnostic and therapeutic procedures and research. These capabilities will support the efforts of the UW SMPH and UW Health to help patients with Alzheimer’s and Parkinson’s disease, cancer, chronic pain, and other conditions.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
